ArticleScientific reports2025
Risk of major adverse cardiovascular events and all-cause mortality in type 2 diabetic patients receiving insulin versus non-insulin treatment intensification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glycemic Control and Diabetes Outcomes After Surgical Therapy for Diabetic Gastroparesis.JAMA surgery · 2026Article
- Technology-driven diabetes care: innovation without equity?Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal timing for initiating insulin therapy in patients with type 2 diabetes (T2D) remains uncertain and varies among clinical guidelines. This retrospective cohort study analyzed claims data to include insulin-naïve T2D patients aged ≥ 20 years who intensified treatment using either insulin or non-insulin therapies between 2012 and 2021. Cox proportional hazards models were applied to estimate hazard ratios (HRs) for major adverse cardiovascular events (MACE) and all-cause mortality, with adjustments for sex, age interval, index year interval, number of outpatient visits, number of inpatient admissions, diabetes duration, Charlson Comorbidity Index (CCI), Diabetes Complication Severity Index (DCSI), the number of prior antidiabetic medications, medications for hypertension, hyperlipidemia, antiplatelets, and anticoagulants. Subgroup analyses stratified by sex, age, the number of prior antidiabetic medications and types of insulin were also performed. Compared to non-insulin intensification, insulin therapy was associated with significantly higher risks of MACE and all-cause mortality. The adjusted HRs (95% confidence intervals [CIs]) were 2.78 (2.64-2.92) for MACE and 4.74 (4.63-4.85) for all-cause mortality. Subgroup analyses revealed consistently elevated risks across all patient groups, with the smallest risk increases observed in patients who had previously used three non-insulin drugs before initiating insulin therapy (HRs for MACE: 2.62 [2.13-3.22]; all-cause mortality: 3.05 [2.68-3.49]). Among insulin types, long-acting insulin was associated with the lowest risk increases (MACE HR: 1.34 [1.19-1.51]; all-cause mortality HR: 1.90 [1.78-2.03]). In conclusion, treatment intensification with insulin was linked to increased risks of MACE and all-cause mortality. The lowest risks were observed in patients initiating long-acting insulin following prior therapy with three non-insulin drugs. These findings highlight the need for careful patient evaluation and individualized decision-making when initiating insulin therapy in T2D management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.